These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 23996078)

  • 21. Establishing population distribution of drug-metabolizing enzyme activities for the use of salivary caffeine as a dynamic liver function marker in a Singaporean Chinese population.
    Chia HY; Yau WP; Ho HK
    Biopharm Drug Dispos; 2016 Apr; 37(3):168-81. PubMed ID: 26862045
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Use of the paraxanthine/caffeine ratio in the saliva of patients with liver cirrhosis].
    Perlík F; Pucelíková T; Slanar O
    Cas Lek Cesk; 2001 Feb; 140(2):51-3. PubMed ID: 11262908
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva.
    Fuhr U; Rost KL
    Pharmacogenetics; 1994 Jun; 4(3):109-16. PubMed ID: 7920690
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytochrome P4501A2: enzyme induction and genetic control in determining 4-aminobiphenyl-hemoglobin adduct levels.
    Landi MT; Zocchetti C; Bernucci I; Kadlubar FF; Tannenbaum S; Skipper P; Bartsch H; Malaveille C; Shields P; Caporaso NE; Vineis P
    Cancer Epidemiol Biomarkers Prev; 1996 Sep; 5(9):693-8. PubMed ID: 8877060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nonparametric expectation maximisation (NPEM) population pharmacokinetic analysis of caffeine disposition from sparse data in adult caucasians: systemic caffeine clearance as a biomarker for cytochrome P450 1A2 activity.
    Terziivanov D; Bozhinova K; Dimitrova V; Atanasova I
    Clin Pharmacokinet; 2003; 42(15):1393-409. PubMed ID: 14674790
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of acute falciparum malaria on the disposition of caffeine and the comparison of saliva and plasma-derived pharmacokinetic parameters in adult Nigerians.
    Akinyinka OO; Sowunmi A; Honeywell R; Renwick AG
    Eur J Clin Pharmacol; 2000 May; 56(2):159-65. PubMed ID: 10877011
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine.
    Carrillo JA; Christensen M; Ramos SI; Alm C; Dahl ML; Benitez J; Bertilsson L
    Ther Drug Monit; 2000 Aug; 22(4):409-17. PubMed ID: 10942180
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Phase 1 Open-Label, Fixed-Sequence Pharmacokinetic Drug Interaction Trial to Investigate the Effect of Cannabidiol on the CYP1A2 Probe Caffeine in Healthy Subjects.
    Thai C; Tayo B; Critchley D
    Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1279-1289. PubMed ID: 33951339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Variation of CYP1A2-dependent caffeine metabolism during menstrual cycle in healthy women.
    Zaigler M; Rietbrock S; Szymanski J; Dericks-Tan JS; Staib AH; Fuhr U
    Int J Clin Pharmacol Ther; 2000 May; 38(5):235-44. PubMed ID: 10839467
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes.
    Campbell ME; Grant DM; Inaba T; Kalow W
    Drug Metab Dispos; 1987; 15(2):237-49. PubMed ID: 2882985
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Accumulation of theophylline, theobromine and paraxanthine in the fetal rat brain following a single oral dose of caffeine.
    Wilkinson JM; Pollard I
    Brain Res Dev Brain Res; 1993 Oct; 75(2):193-9. PubMed ID: 8261611
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Why dried blood spots are an ideal tool for CYP1A2 phenotyping.
    De Kesel PM; Lambert WE; Stove CP
    Clin Pharmacokinet; 2014 Aug; 53(8):763-71. PubMed ID: 24980692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of CYP1A2 activity in clinical practice: why, how, and when?
    Faber MS; Jetter A; Fuhr U
    Basic Clin Pharmacol Toxicol; 2005 Sep; 97(3):125-34. PubMed ID: 16128905
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of venlafaxine on CYP1A2-dependent pharmacokinetics and metabolism of caffeine.
    Amchin J; Zarycranski W; Taylor KP; Albano D; Klockowski PM
    J Clin Pharmacol; 1999 Mar; 39(3):252-9. PubMed ID: 10073324
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of CYP1A2 activity: Relationship between the endogenous urinary 6-hydroxymelatonin to melatonin ratio and paraxanthine to caffeine ratio in dried blood spots.
    Magliocco G; Desmeules J; Samer CF; Thomas A; Daali Y
    Clin Transl Sci; 2022 Jun; 15(6):1482-1491. PubMed ID: 35338582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of long-term ethanol consumption on CYP1A2 activity.
    Rizzo N; Hispard E; Dolbeault S; Dally S; Leverge R; Girre C
    Clin Pharmacol Ther; 1997 Nov; 62(5):505-9. PubMed ID: 9390106
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2.
    Plowchalk DR; Rowland Yeo K
    Eur J Clin Pharmacol; 2012 Jun; 68(6):951-60. PubMed ID: 22258279
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The pharmacokinetics of caffeine in Nigerian children suffering from malaria and kwashiorkor.
    Akinyinka OO; Sowunmi A; Honeywell R; Renwick AG
    Eur J Clin Pharmacol; 2000 May; 56(2):153-8. PubMed ID: 10877010
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of paraxanthine, one of the primary metabolites of caffeine, in the rat.
    Bortolotti A; Jiritano L; Bonati M
    Drug Metab Dispos; 1985; 13(2):227-31. PubMed ID: 2859173
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Five caffeine metabolite ratios to measure tobacco-induced CYP1A2 activity and their relationships with urinary mutagenicity and urine flow.
    Sinués B; Sáenz MA; Lanuza J; Bernal ML; Fanlo A; Juste JL; Mayayo E
    Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):159-66. PubMed ID: 10067814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.